Eli Lilly company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
Investors bid up AtaiBeckley (ATAI) after Eli Lilly agreed to acquire the company in a deal that could total as much as $3.8 billion, pushing ATAI to its highest level in about four years.
THE APEX TIMES
THE APEX TIMES
The proposed cash buyout values AtaiBeckley at about $2.8 billion and includes additional payments tied to future milestones, according to a report.
THE APEX TIMES
The deal price underscores how aggressively Big Pharma is pursuing faster-moving approaches to depression, even as pivotal clinical readouts are still years away.
THE APEX TIMES
UBS pointed to positive clinical readouts tied to Lilly’s amylin and tirzepatide programs as potential catalysts, suggesting the company’s obesity and metabolic pipeline could keep moving in investors’ favor.
THE APEX TIMES
Europe’s approval of an oral version of Wegovy gives Novo Nordisk another lead in the race against Eli Lilly’s weight-loss pipeline, according to reporting.
THE APEX TIMES
A market report says Eli Lilly is in talks about buying ATAI, sending ATAI’s stock sharply higher as investors wait for details on whether a deal is actually being structured.
THE APEX TIMES
The announcement lifted AtaiBeckley shares by more than 30% on Thursday, as the companies positioned the acquisition around expanding Lilly’s neuroscience development efforts.
THE APEX TIMES
The acquisition is framed as Lilly’s first entry into psychedelic medicine, aimed at expanding a broader pipeline beyond its core therapeutic areas.
THE APEX TIMES
A new comparison of Johnson & Johnson and Eli Lilly frames one company as a steadier cash generator with a lower valuation, while the other is described as posting roughly 45% growth but carrying higher leverage.
